Caplacizumab - Ablynx

Drug Profile

Caplacizumab - Ablynx

Alternative Names: ALX-0081; ALX-0681; Anti-von Willebrand factor Nanobody® - Ablynx; Cablivi

Latest Information Update: 13 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ablynx
  • Class Anticoagulants; Antithrombotics; Monoclonal antibodies; Proteins; Recombinant proteins; Single-domain antibodies
  • Mechanism of Action Platelet aggregation inhibitors; Von Willebrand factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thrombotic thrombocytopenic purpura
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Thrombotic thrombocytopenic purpura
  • Discontinued Thrombosis

Most Recent Events

  • 29 Jun 2018 Ablynx and Sanofi announce intention to submit BLA to the US FDA for Thrombotic thrombocytopenic purpura in the first half of 2018
  • 29 Jun 2018 The Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion and recommended approval of caplacizumab (Cablivi™) for the treatment of acquired thrombotic thrombocytopenic purpura
  • 19 Jun 2018 Ablynx has been acquired by Sanofi
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top